Gilead Sciences, Inc.

(NASDAQ Global Select)
Back to all articles
Somewhat Bullish +45

9,474 Shares in Gilead Sciences, Inc. $GILD Acquired by Dorsey Wright ...

AI-generated analysis

πŸ“ˆ Dorsey Wright & Associates acquired a new position in Gilead Sciences valued at approximately $1.32 million during the first quarter.

πŸ“Š Institutional ownership stands at 83.67%, with multiple hedge funds like Ieq Capital LLC and Sivia Capital Partners increasing their stakes significantly.

πŸ“‰ CEO Daniel Patrick O'day sold 15,000 shares for $1.89 million in July under a pre-arranged trading plan, representing a 2.41% decrease in his holdings.

πŸ’° Gilead reported quarterly revenue of $6.96 billion and EPS of $2.03, beating analyst estimates by $50 million and $0.12 respectively.

πŸ“ˆ Analyst consensus is 'Moderate Buy' with an average target price of $159.04, though some firms like Daiwa Securities lowered targets to $150.

πŸ’΅ The company recently paid a quarterly dividend of $0.82 per share, resulting in an annualized yield of 2.4% for shareholders.

πŸ“‰ Financial metrics show a price-to-earnings ratio of 18.29 and a debt-to-equity ratio of 0.89, indicating a stable financial position.

🌍 Gilead focuses on antiviral therapies for HIV and hepatitis, with expansion into oncology, cell therapy, and inflammatory diseases.

Bullish Signals
  • Gilead Sciences beat quarterly revenue estimates by $50 million to reach $6.96 billion, demonstrating strong commercial performance.
  • The company exceeded earnings per share expectations with a reported EPS of $2.03 compared to the consensus of $1.91.
  • Multiple institutional investors including Dorsey Wright & Associates and Ieq Capital LLC have increased or established new positions in the stock.
  • Analysts maintain a 'Moderate Buy' consensus rating with an average target price of $159.04, suggesting continued confidence in the business.
  • Gilead maintains a robust balance sheet with a debt-to-equity ratio of 0.89 and a current ratio of 1.97.
Risk Factors
  • CEO Daniel Patrick O'day sold 15,000 shares worth $1.89 million in July, signaling a reduction in personal equity exposure.
  • Daiwa Securities Group lowered its price target from $161.00 to $150.00, indicating some analysts see limited upside potential.
  • Royal Bank Of Canada reduced its price target to $120.00 and assigned a 'sector perform' rating, reflecting cautious sentiment.
  • Weiss Ratings downgraded the stock from a 'buy (b)' to a 'buy (b-)', suggesting a slight reduction in investment quality perception.
Full Analysis
Gilead Sciences, Inc. (NASDAQ: GILD) saw activity from several institutional investors in the first quarter of 2026. Dorsey Wright & Associates acquired a new position valued at approximately $1.32 million for 9,474 shares. Other funds including Brighton Jones LLC, Bison Wealth LLC, Sivia Capital Partners LLC, Ieq Capital LLC, and Diversify Advisory Services LLC also increased their stakes or established new positions during the second and fourth quarters. Analyst sentiment remains mixed with a consensus 'Moderate Buy' rating and an average target price of $159.04. Truist Financial and Maxim Group recently upgraded or maintained buy ratings, while Daiwa Securities Group and Royal Bank Of Canada lowered their price targets to $150.00 and $120.00 respectively. Weiss Ratings slightly downgraded the stock from a 'buy (b)' to a 'buy (b-)' rating. Insider trading activity shows CEO Daniel Patrick O'day sold 15,000 shares in July for approximately $1.89 million under a pre-arranged Rule 10b5-1 plan, reducing his ownership by 2.41%. CFO Johanna Mercier also sold 3,000 shares in June. Over the last ninety days, insiders collectively sold 77,000 shares worth nearly $10 million, though they still hold a significant portion of the company's stock. Financially, Gilead reported strong quarterly results with revenue of $6.96 billion, beating estimates by $50 million, and EPS of $2.03 versus a consensus of $1.91. The company maintains a healthy balance sheet with a debt-to-equity ratio of 0.89 and recently paid a quarterly dividend of $0.82 per share, yielding 2.4%.